 Mary Hayden
Concepts (375)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 35 | 2018 | 257 | 7.220 |
Why?
| | beta-Lactamases | 22 | 2018 | 64 | 5.660 |
Why?
| | Klebsiella pneumoniae | 15 | 2018 | 50 | 4.930 |
Why?
| | Bacterial Proteins | 22 | 2017 | 78 | 4.700 |
Why?
| | Klebsiella Infections | 15 | 2018 | 48 | 3.790 |
Why?
| | Anti-Bacterial Agents | 31 | 2019 | 349 | 3.760 |
Why?
| | Gram-Positive Bacterial Infections | 20 | 2014 | 62 | 3.620 |
Why?
| | Chlorhexidine | 14 | 2019 | 47 | 3.560 |
Why?
| | Vancomycin Resistance | 12 | 2014 | 31 | 3.520 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 14 | 2019 | 80 | 3.400 |
Why?
| | Infection Control | 21 | 2019 | 138 | 3.200 |
Why?
| | Enterococcus | 21 | 2014 | 63 | 3.200 |
Why?
| | Enterobacteriaceae | 6 | 2016 | 34 | 2.600 |
Why?
| | Carrier State | 16 | 2019 | 52 | 2.600 |
Why?
| | Bacteremia | 17 | 2019 | 106 | 2.300 |
Why?
| | Staphylococcal Infections | 16 | 2019 | 142 | 2.250 |
Why?
| | Disease Outbreaks | 13 | 2017 | 88 | 2.210 |
Why?
| | Enterobacteriaceae Infections | 6 | 2018 | 35 | 2.170 |
Why?
| | Intensive Care Units | 22 | 2019 | 227 | 2.120 |
Why?
| | Anti-Infective Agents, Local | 9 | 2019 | 45 | 2.030 |
Why?
| | Baths | 7 | 2019 | 23 | 1.800 |
Why?
| | Drug Resistance, Multiple, Bacterial | 7 | 2019 | 31 | 1.720 |
Why?
| | Drug Resistance, Bacterial | 8 | 2018 | 50 | 1.670 |
Why?
| | Housekeeping, Hospital | 3 | 2014 | 5 | 1.540 |
Why?
| | Escherichia coli | 4 | 2018 | 66 | 1.490 |
Why?
| | Carbapenems | 6 | 2018 | 25 | 1.470 |
Why?
| | Humans | 96 | 2019 | 24408 | 1.410 |
Why?
| | Mupirocin | 6 | 2019 | 14 | 1.340 |
Why?
| | Skin | 10 | 2014 | 114 | 1.320 |
Why?
| | beta-Lactam Resistance | 4 | 2015 | 17 | 1.260 |
Why?
| | Long-Term Care | 7 | 2017 | 53 | 1.260 |
Why?
| | Vancomycin | 13 | 2006 | 48 | 1.240 |
Why?
| | Microbial Sensitivity Tests | 18 | 2018 | 107 | 1.210 |
Why?
| | Skin Care | 3 | 2012 | 12 | 1.200 |
Why?
| | Disinfection | 4 | 2019 | 10 | 1.120 |
Why?
| | Enterococcus faecium | 6 | 2008 | 15 | 1.050 |
Why?
| | Population Surveillance | 6 | 2017 | 108 | 1.050 |
Why?
| | Bacteriological Techniques | 3 | 2017 | 20 | 1.030 |
Why?
| | Culture Media | 5 | 2017 | 37 | 1.030 |
Why?
| | Mass Screening | 5 | 2018 | 155 | 0.970 |
Why?
| | Catheterization, Central Venous | 2 | 2010 | 44 | 0.970 |
Why?
| | Hospitals | 12 | 2017 | 105 | 0.960 |
Why?
| | beta-Lactams | 2 | 2010 | 11 | 0.950 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 13 | 2014 | 40 | 0.940 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 3 | 2010 | 6 | 0.940 |
Why?
| | Genome, Bacterial | 3 | 2017 | 13 | 0.940 |
Why?
| | Middle Aged | 44 | 2019 | 9105 | 0.930 |
Why?
| | Dengue | 3 | 2016 | 3 | 0.910 |
Why?
| | Female | 51 | 2019 | 14387 | 0.900 |
Why?
| | Escherichia coli Infections | 5 | 2018 | 32 | 0.870 |
Why?
| | Male | 48 | 2019 | 14131 | 0.840 |
Why?
| | Chicago | 18 | 2018 | 740 | 0.790 |
Why?
| | Aged | 32 | 2019 | 8058 | 0.750 |
Why?
| | Dengue Virus | 1 | 2015 | 1 | 0.740 |
Why?
| | Gram-Positive Bacteria | 2 | 2012 | 18 | 0.730 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2014 | 7 | 0.710 |
Why?
| | Virulence Factors | 1 | 2014 | 11 | 0.710 |
Why?
| | Bacterial Toxins | 1 | 2014 | 20 | 0.700 |
Why?
| | Bacterial Load | 3 | 2013 | 12 | 0.680 |
Why?
| | Acinetobacter baumannii | 1 | 2014 | 3 | 0.680 |
Why?
| | Acinetobacter Infections | 1 | 2014 | 4 | 0.680 |
Why?
| | Anal Canal | 1 | 2014 | 13 | 0.670 |
Why?
| | Hand | 5 | 2008 | 49 | 0.670 |
Why?
| | Drug Resistance, Microbial | 13 | 1999 | 99 | 0.670 |
Why?
| | Equipment Contamination | 3 | 2012 | 21 | 0.650 |
Why?
| | Methicillin Resistance | 4 | 2007 | 33 | 0.630 |
Why?
| | Community-Acquired Infections | 7 | 2014 | 66 | 0.620 |
Why?
| | Gloves, Protective | 3 | 2008 | 11 | 0.620 |
Why?
| | Staphylococcus aureus | 4 | 2019 | 79 | 0.570 |
Why?
| | Gram-Negative Bacterial Infections | 3 | 2008 | 27 | 0.550 |
Why?
| | Sensitivity and Specificity | 7 | 2015 | 553 | 0.540 |
Why?
| | Critical Care | 2 | 2010 | 169 | 0.540 |
Why?
| | Rectum | 8 | 2018 | 62 | 0.540 |
Why?
| | Adult | 28 | 2019 | 7917 | 0.520 |
Why?
| | Fomites | 1 | 2008 | 4 | 0.470 |
Why?
| | Decontamination | 1 | 2008 | 10 | 0.470 |
Why?
| | DNA, Bacterial | 7 | 2017 | 51 | 0.470 |
Why?
| | Aedes | 3 | 2017 | 3 | 0.460 |
Why?
| | Disinfectants | 3 | 2014 | 10 | 0.450 |
Why?
| | Minisatellite Repeats | 1 | 2008 | 7 | 0.450 |
Why?
| | Endemic Diseases | 1 | 2008 | 7 | 0.450 |
Why?
| | Aged, 80 and over | 14 | 2018 | 4083 | 0.440 |
Why?
| | Skilled Nursing Facilities | 3 | 2018 | 10 | 0.430 |
Why?
| | Polymerase Chain Reaction | 5 | 2016 | 205 | 0.430 |
Why?
| | Genes, Bacterial | 2 | 2016 | 7 | 0.410 |
Why?
| | Specimen Handling | 2 | 2017 | 45 | 0.410 |
Why?
| | Bacteria | 2 | 2017 | 62 | 0.410 |
Why?
| | Hand Disinfection | 4 | 2010 | 18 | 0.400 |
Why?
| | Sequence Analysis, DNA | 4 | 2017 | 94 | 0.400 |
Why?
| | Serratia marcescens | 3 | 2011 | 12 | 0.400 |
Why?
| | Gram-Negative Bacteria | 4 | 2013 | 39 | 0.400 |
Why?
| | Serratia Infections | 3 | 2011 | 11 | 0.400 |
Why?
| | Daptomycin | 1 | 2005 | 17 | 0.370 |
Why?
| | Risk Factors | 11 | 2017 | 2055 | 0.370 |
Why?
| | Prevalence | 8 | 2015 | 450 | 0.370 |
Why?
| | Asthma, Exercise-Induced | 1 | 2003 | 2 | 0.330 |
Why?
| | Nasal Cavity | 5 | 2014 | 26 | 0.330 |
Why?
| | Drug Resistance, Multiple | 2 | 2012 | 12 | 0.330 |
Why?
| | Time Factors | 7 | 2017 | 1584 | 0.330 |
Why?
| | Drug Therapy, Combination | 2 | 1994 | 245 | 0.320 |
Why?
| | Pseudomonas aeruginosa | 2 | 2018 | 82 | 0.320 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 316 | 0.320 |
Why?
| | Models, Statistical | 2 | 2015 | 126 | 0.320 |
Why?
| | Environment | 2 | 2017 | 55 | 0.320 |
Why?
| | Molecular Epidemiology | 6 | 2015 | 23 | 0.310 |
Why?
| | Case-Control Studies | 6 | 2017 | 555 | 0.300 |
Why?
| | Disease Reservoirs | 3 | 2010 | 10 | 0.270 |
Why?
| | Florida | 3 | 2016 | 17 | 0.270 |
Why?
| | Drug Contamination | 2 | 2011 | 7 | 0.270 |
Why?
| | Prisons | 2 | 2013 | 11 | 0.260 |
Why?
| | Sepsis | 2 | 2014 | 132 | 0.260 |
Why?
| | Loiasis | 1 | 1998 | 3 | 0.230 |
Why?
| | Eye Infections, Parasitic | 1 | 1998 | 4 | 0.230 |
Why?
| | West Nile Fever | 2 | 2016 | 5 | 0.230 |
Why?
| | Environmental Microbiology | 2 | 2017 | 4 | 0.230 |
Why?
| | Comorbidity | 2 | 2019 | 460 | 0.230 |
Why?
| | Temperature | 2 | 2017 | 80 | 0.230 |
Why?
| | Treatment Outcome | 8 | 2013 | 2996 | 0.230 |
Why?
| | Conjugation, Genetic | 2 | 1997 | 5 | 0.220 |
Why?
| | Bacterial Typing Techniques | 4 | 2011 | 13 | 0.220 |
Why?
| | Personnel, Hospital | 2 | 2008 | 14 | 0.210 |
Why?
| | Hospitalization | 4 | 2019 | 237 | 0.210 |
Why?
| | Glycopeptides | 1 | 1997 | 3 | 0.210 |
Why?
| | Thailand | 2 | 2014 | 13 | 0.210 |
Why?
| | Models, Theoretical | 1 | 2017 | 91 | 0.210 |
Why?
| | Teicoplanin | 2 | 1994 | 5 | 0.200 |
Why?
| | Selection, Genetic | 1 | 2016 | 6 | 0.200 |
Why?
| | Ciprofloxacin | 3 | 2008 | 33 | 0.200 |
Why?
| | Chromogenic Compounds | 2 | 2013 | 3 | 0.200 |
Why?
| | Feces | 1 | 2017 | 85 | 0.200 |
Why?
| | Mosquito Control | 1 | 2016 | 1 | 0.200 |
Why?
| | Critical Illness | 2 | 2015 | 79 | 0.190 |
Why?
| | Financing, Government | 1 | 2016 | 14 | 0.190 |
Why?
| | Animals | 7 | 2017 | 4688 | 0.190 |
Why?
| | Candidiasis | 1 | 2015 | 14 | 0.190 |
Why?
| | Melioidosis | 1 | 2015 | 3 | 0.190 |
Why?
| | Burkholderia pseudomallei | 1 | 2015 | 3 | 0.190 |
Why?
| | Models, Biological | 2 | 2014 | 408 | 0.190 |
Why?
| | Levofloxacin | 1 | 1995 | 4 | 0.190 |
Why?
| | Ofloxacin | 1 | 1995 | 5 | 0.190 |
Why?
| | Travel | 1 | 2015 | 14 | 0.190 |
Why?
| | Health Personnel | 3 | 2008 | 70 | 0.190 |
Why?
| | Urinary Tract Infections | 1 | 2015 | 21 | 0.190 |
Why?
| | Markov Chains | 1 | 2015 | 31 | 0.190 |
Why?
| | Rain | 1 | 2015 | 1 | 0.180 |
Why?
| | West Nile virus | 1 | 2015 | 2 | 0.180 |
Why?
| | Monte Carlo Method | 1 | 2015 | 54 | 0.180 |
Why?
| | Adolescent | 9 | 2018 | 2161 | 0.180 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2015 | 6 | 0.180 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2015 | 8 | 0.180 |
Why?
| | Biomedical Research | 1 | 2016 | 70 | 0.180 |
Why?
| | Water Microbiology | 1 | 2015 | 10 | 0.180 |
Why?
| | Soaps | 3 | 2010 | 10 | 0.180 |
Why?
| | Hospitals, University | 1 | 2015 | 45 | 0.180 |
Why?
| | Data Collection | 1 | 2015 | 115 | 0.170 |
Why?
| | Pharynx | 1 | 2014 | 8 | 0.170 |
Why?
| | Patient Care | 2 | 2013 | 28 | 0.170 |
Why?
| | Cost Savings | 1 | 2014 | 32 | 0.170 |
Why?
| | Medical Staff, Hospital | 1 | 2014 | 17 | 0.170 |
Why?
| | Mandatory Reporting | 1 | 2013 | 5 | 0.170 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2013 | 5 | 0.160 |
Why?
| | Colorimetry | 1 | 2013 | 1 | 0.160 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2013 | 12 | 0.160 |
Why?
| | United States | 6 | 2017 | 1854 | 0.160 |
Why?
| | Multivariate Analysis | 4 | 2013 | 340 | 0.160 |
Why?
| | Air Microbiology | 1 | 2013 | 3 | 0.160 |
Why?
| | Fungi | 1 | 2013 | 6 | 0.160 |
Why?
| | Aerosols | 1 | 2013 | 14 | 0.160 |
Why?
| | Cohort Studies | 2 | 2012 | 1448 | 0.160 |
Why?
| | Poisson Distribution | 2 | 2010 | 26 | 0.160 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 155 | 0.150 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 22 | 0.150 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 56 | 0.150 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 24 | 0.150 |
Why?
| | Quality of Health Care | 1 | 2013 | 117 | 0.150 |
Why?
| | Hospital Administration | 2 | 2014 | 15 | 0.140 |
Why?
| | Patient Transfer | 1 | 2012 | 22 | 0.140 |
Why?
| | Hospitals, Teaching | 4 | 2010 | 33 | 0.140 |
Why?
| | Cluster Analysis | 3 | 2018 | 54 | 0.130 |
Why?
| | Staphylococcal Skin Infections | 2 | 2007 | 14 | 0.130 |
Why?
| | Soft Tissue Infections | 2 | 2007 | 21 | 0.130 |
Why?
| | Enterococcus faecalis | 2 | 2002 | 8 | 0.130 |
Why?
| | Multilocus Sequence Typing | 3 | 2016 | 10 | 0.120 |
Why?
| | Blood | 1 | 2009 | 23 | 0.120 |
Why?
| | Administration, Intranasal | 2 | 2019 | 22 | 0.120 |
Why?
| | Infant | 3 | 2016 | 522 | 0.120 |
Why?
| | Prospective Studies | 5 | 2012 | 1375 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2009 | 119 | 0.120 |
Why?
| | Severe Dengue | 1 | 2008 | 1 | 0.110 |
Why?
| | Imipenem | 1 | 2008 | 7 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2008 | 57 | 0.110 |
Why?
| | Public Housing | 1 | 2007 | 3 | 0.110 |
Why?
| | Catheterization | 1 | 2007 | 55 | 0.110 |
Why?
| | Indicators and Reagents | 1 | 2007 | 20 | 0.110 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 20 | 0.100 |
Why?
| | Simplexvirus | 1 | 2006 | 11 | 0.100 |
Why?
| | Hepatitis | 1 | 2006 | 9 | 0.100 |
Why?
| | DNA, Viral | 1 | 2007 | 103 | 0.100 |
Why?
| | Disease Transmission, Infectious | 2 | 2019 | 8 | 0.100 |
Why?
| | Syringes | 3 | 2011 | 10 | 0.100 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 42 | 0.100 |
Why?
| | Colony Count, Microbial | 3 | 2015 | 22 | 0.100 |
Why?
| | Immunosuppression | 1 | 2006 | 38 | 0.100 |
Why?
| | Cytomegalovirus | 1 | 2007 | 78 | 0.100 |
Why?
| | Viral Load | 1 | 2007 | 185 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2007 | 78 | 0.100 |
Why?
| | Program Evaluation | 1 | 2007 | 130 | 0.100 |
Why?
| | Geography | 2 | 2017 | 19 | 0.100 |
Why?
| | Retrospective Studies | 2 | 2018 | 2402 | 0.100 |
Why?
| | HIV Infections | 1 | 2013 | 760 | 0.100 |
Why?
| | Culex | 2 | 2016 | 3 | 0.090 |
Why?
| | Osteomyelitis | 1 | 2005 | 23 | 0.090 |
Why?
| | Child | 4 | 2016 | 1230 | 0.090 |
Why?
| | Lumbosacral Region | 1 | 2005 | 43 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1997 | 46 | 0.090 |
Why?
| | Phylogeny | 2 | 2015 | 76 | 0.090 |
Why?
| | Ampicillin | 2 | 1995 | 9 | 0.090 |
Why?
| | Treatment Failure | 1 | 2005 | 152 | 0.090 |
Why?
| | Young Adult | 3 | 2018 | 1656 | 0.090 |
Why?
| | Kidney Transplantation | 1 | 2006 | 113 | 0.090 |
Why?
| | Illinois | 3 | 2015 | 205 | 0.090 |
Why?
| | Ascomycota | 1 | 2004 | 2 | 0.090 |
Why?
| | Mitosporic Fungi | 1 | 2004 | 2 | 0.090 |
Why?
| | Fungemia | 1 | 2004 | 4 | 0.090 |
Why?
| | Drug Synergism | 2 | 1994 | 62 | 0.090 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2004 | 12 | 0.090 |
Why?
| | Infant, Newborn | 3 | 2016 | 597 | 0.090 |
Why?
| | Mycoses | 1 | 2004 | 20 | 0.090 |
Why?
| | Aminoglycosides | 2 | 2013 | 12 | 0.090 |
Why?
| | Membrane Transport Proteins | 2 | 2014 | 44 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2004 | 92 | 0.080 |
Why?
| | Hemolysin Proteins | 1 | 2002 | 2 | 0.080 |
Why?
| | Gelatinases | 1 | 2002 | 4 | 0.080 |
Why?
| | Mexico | 2 | 2015 | 16 | 0.080 |
Why?
| | Nurse's Role | 1 | 2003 | 126 | 0.070 |
Why?
| | Mathematics | 1 | 2000 | 34 | 0.070 |
Why?
| | Lumbar Vertebrae | 1 | 2005 | 365 | 0.070 |
Why?
| | Heparin | 2 | 2011 | 37 | 0.060 |
Why?
| | Cephalosporins | 2 | 1998 | 16 | 0.060 |
Why?
| | Child, Preschool | 2 | 2016 | 663 | 0.060 |
Why?
| | Sodium Chloride | 2 | 2011 | 42 | 0.060 |
Why?
| | Statistics as Topic | 2 | 2015 | 124 | 0.060 |
Why?
| | Plasmids | 2 | 2016 | 50 | 0.060 |
Why?
| | Carbon-Oxygen Ligases | 1 | 1999 | 2 | 0.060 |
Why?
| | Hygiene | 1 | 2019 | 15 | 0.060 |
Why?
| | Confidence Intervals | 2 | 2012 | 105 | 0.060 |
Why?
| | Integrons | 1 | 2018 | 2 | 0.060 |
Why?
| | Incidence | 2 | 2015 | 649 | 0.060 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 48 | 0.060 |
Why?
| | Genotype | 1 | 1999 | 372 | 0.050 |
Why?
| | Chromosomes, Bacterial | 1 | 1997 | 2 | 0.050 |
Why?
| | Surgical Wound Infection | 1 | 1999 | 91 | 0.050 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 1997 | 10 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2019 | 164 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 42 | 0.050 |
Why?
| | Gloves, Surgical | 1 | 1996 | 2 | 0.050 |
Why?
| | Protective Clothing | 1 | 1996 | 6 | 0.050 |
Why?
| | Ceftazidime | 1 | 1996 | 13 | 0.050 |
Why?
| | Length of Stay | 2 | 2014 | 277 | 0.050 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 47 | 0.050 |
Why?
| | Arizona | 1 | 2016 | 3 | 0.050 |
Why?
| | Outcome Assessment (Health Care) | 1 | 2019 | 273 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2016 | 77 | 0.050 |
Why?
| | Respiration, Artificial | 2 | 2012 | 81 | 0.050 |
Why?
| | Bacteriuria | 1 | 2015 | 5 | 0.050 |
Why?
| | Candida | 1 | 2015 | 12 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2017 | 352 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 37 | 0.050 |
Why?
| | Borrelia burgdorferi Group | 1 | 1995 | 6 | 0.050 |
Why?
| | Ticks | 1 | 1995 | 5 | 0.050 |
Why?
| | Penicillins | 1 | 1995 | 11 | 0.050 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2015 | 13 | 0.050 |
Why?
| | Genomics | 1 | 2015 | 21 | 0.050 |
Why?
| | Insect Vectors | 1 | 2015 | 2 | 0.050 |
Why?
| | Climate | 1 | 2015 | 3 | 0.050 |
Why?
| | Gastric Juice | 1 | 2015 | 4 | 0.050 |
Why?
| | Drinking Water | 1 | 2015 | 5 | 0.050 |
Why?
| | Sputum | 1 | 2015 | 23 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 19 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 1995 | 57 | 0.040 |
Why?
| | Seasons | 1 | 2015 | 36 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 1999 | 1082 | 0.040 |
Why?
| | Public Health | 1 | 2015 | 45 | 0.040 |
Why?
| | Drugs, Investigational | 1 | 1994 | 9 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 304 | 0.040 |
Why?
| | Gentamicins | 1 | 1994 | 13 | 0.040 |
Why?
| | Genetic Markers | 1 | 2014 | 47 | 0.040 |
Why?
| | Organizational Culture | 1 | 2014 | 19 | 0.040 |
Why?
| | Campylobacter Infections | 1 | 2014 | 11 | 0.040 |
Why?
| | Diffusion | 1 | 2014 | 31 | 0.040 |
Why?
| | Sex Factors | 1 | 2015 | 416 | 0.040 |
Why?
| | Focus Groups | 1 | 2014 | 69 | 0.040 |
Why?
| | Reimbursement, Incentive | 1 | 2013 | 6 | 0.040 |
Why?
| | Species Specificity | 1 | 2014 | 76 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2014 | 67 | 0.040 |
Why?
| | Qualitative Research | 1 | 2014 | 79 | 0.040 |
Why?
| | Longevity | 1 | 2014 | 31 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2013 | 9 | 0.040 |
Why?
| | Colistin | 1 | 2013 | 4 | 0.040 |
Why?
| | Chickens | 1 | 2014 | 53 | 0.040 |
Why?
| | Hospitals, Public | 2 | 2007 | 30 | 0.040 |
Why?
| | Minocycline | 1 | 2013 | 8 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2013 | 7 | 0.040 |
Why?
| | Hospital Costs | 1 | 2014 | 66 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2019 | 1690 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 6 | 0.040 |
Why?
| | Phenotype | 1 | 2014 | 312 | 0.040 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 170 | 0.040 |
Why?
| | Ventilation | 1 | 2013 | 3 | 0.040 |
Why?
| | Nose | 1 | 2013 | 25 | 0.040 |
Why?
| | Nursing Homes | 1 | 2012 | 29 | 0.040 |
Why?
| | Propensity Score | 1 | 2012 | 37 | 0.040 |
Why?
| | Agar | 1 | 2012 | 1 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2007 | 318 | 0.040 |
Why?
| | Contact Tracing | 1 | 2011 | 6 | 0.040 |
Why?
| | Indiana | 1 | 2011 | 17 | 0.040 |
Why?
| | Odds Ratio | 1 | 2012 | 269 | 0.040 |
Why?
| | Serratia | 1 | 2010 | 7 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2010 | 121 | 0.030 |
Why?
| | APACHE | 2 | 2001 | 28 | 0.030 |
Why?
| | Patient Isolation | 1 | 2010 | 23 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2012 | 691 | 0.030 |
Why?
| | Drug and Narcotic Control | 1 | 2009 | 8 | 0.030 |
Why?
| | Isotonic Solutions | 1 | 2009 | 17 | 0.030 |
Why?
| | Safety | 1 | 2009 | 53 | 0.030 |
Why?
| | Quality Control | 1 | 2009 | 46 | 0.030 |
Why?
| | Drug Industry | 1 | 2009 | 28 | 0.030 |
Why?
| | China | 1 | 2009 | 117 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 70 | 0.030 |
Why?
| | Texas | 1 | 2008 | 10 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2008 | 19 | 0.030 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2008 | 11 | 0.030 |
Why?
| | Neural Tube Defects | 1 | 2008 | 10 | 0.030 |
Why?
| | Porins | 1 | 2008 | 23 | 0.030 |
Why?
| | Bedding and Linens | 1 | 2007 | 5 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2007 | 63 | 0.030 |
Why?
| | Methicillin | 1 | 2007 | 4 | 0.030 |
Why?
| | Blotting, Western | 1 | 2008 | 225 | 0.030 |
Why?
| | Gram-Positive Cocci | 1 | 2007 | 5 | 0.030 |
Why?
| | Alcohols | 1 | 2007 | 9 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 47 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2006 | 8 | 0.020 |
Why?
| | Patients | 1 | 2006 | 15 | 0.020 |
Why?
| | Cytomegalovirus Infections | 1 | 2007 | 78 | 0.020 |
Why?
| | Asphyxia Neonatorum | 1 | 1984 | 1 | 0.020 |
Why?
| | Animals, Newborn | 1 | 1984 | 76 | 0.020 |
Why?
| | Probability | 1 | 2004 | 90 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2007 | 698 | 0.020 |
Why?
| | Blood Glucose | 1 | 1984 | 109 | 0.020 |
Why?
| | Survival Analysis | 1 | 2004 | 351 | 0.020 |
Why?
| | Virulence | 1 | 2002 | 12 | 0.020 |
Why?
| | Drug Resistance | 1 | 2002 | 62 | 0.020 |
Why?
| | Mortality | 1 | 2002 | 56 | 0.020 |
Why?
| | Prognosis | 1 | 2004 | 797 | 0.020 |
Why?
| | Risk Assessment | 1 | 2004 | 636 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2004 | 1054 | 0.020 |
Why?
| | Hospital Bed Capacity, 500 and over | 1 | 1998 | 10 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1999 | 29 | 0.010 |
Why?
| | Enteral Nutrition | 1 | 1998 | 48 | 0.010 |
Why?
| | Risk | 1 | 1998 | 203 | 0.010 |
Why?
| | Genetic Variation | 1 | 1998 | 105 | 0.010 |
Why?
| | Digestive System | 1 | 1996 | 19 | 0.010 |
Why?
| | Sequence Analysis | 1 | 1995 | 4 | 0.010 |
Why?
| | Sequence Alignment | 1 | 1995 | 32 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1995 | 267 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1995 | 331 | 0.010 |
Why?
| | Glucagon | 1 | 1984 | 3 | 0.010 |
Why?
| | Pyruvates | 1 | 1984 | 3 | 0.010 |
Why?
| | Lactates | 1 | 1984 | 10 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1984 | 51 | 0.010 |
Why?
| | Glycogen | 1 | 1984 | 9 | 0.010 |
Why?
| | Catecholamines | 1 | 1984 | 16 | 0.010 |
Why?
| | Insulin | 1 | 1984 | 88 | 0.010 |
Why?
| | Liver | 1 | 1984 | 195 | 0.000 |
Why?
| | Rats | 1 | 1984 | 947 | 0.000 |
Why?
|
|
Hayden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|